Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2474-2484

  Vermeulen, P E ^a   Gasparini, G ^b   Fox, S B ^c   Toi, M ^d   Martin, L ^e   McCulloch, P ^e   Pezzella, F ^f   Viale, G ^g   Weidner, N ^h   Harris, A L ^c   Dirix, L Y ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b SAN BORTOLO HOSPITAL   (Italy)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; ENDOTHELIAL CELL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; CELL PROLIFERATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MUTATION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR CELL;

EID: 0030512898     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00379-6     Document Type: Article

References (78)

1. 1. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995, 333, 1757-1763.
2. 2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82, 4-6.
3. 3. Pili R, Guo Y, Chang J, et al. Altered angiogenesis underlying age-dependent changes in tumor growth. J Natl Cancer Inst 1994, 86, 1303-1314.
4. 4. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265, 1582-1584.
5. 5. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogens 1994, 9, 963-969.
6. 6. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/NPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995, 55, 4575-4580.
7. 7. Schweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-845.
8. 8. Kuwabara K, Ogawa S, Matsumoto M, et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 1995, 92, 4606-4610.
9. 9. Folkman J. Tumor angiogenesis and tissue factor. Nature Med 1996, 2, 167-168.
10. 10. Vermeulen PB, Verhoeven D, Hubens G, et al. Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol 1995, 6, 59-64.
11. 11. Fox BS, Gatter KC, Bickness R, et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 1993, 53, 4161-4163.
12. 12. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung cancer. Br J Cancer 1996, 73, 931-934.
13. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96, 1815-1822.
14. 14. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationship of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974, 34, 997-1004.
15. 15. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 1995, 346, 1334-1335.
16. 16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995, 1, 27-31.
17. 17. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1995. 1, 961-964.
18. 18. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995, 36, 193-204.
19. 19. Toi M, Hoshino S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994, 85, 1045-1049.
20. 20. Toi M, Kondo S, Suzuki H, et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996, 77, 1101-1106.
21. 21. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995, 55, 1189-1193.
22. 22. Takano S, Yoshii Y, Kondo S, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996, 56, 2185-2190.
23. 23. Li VW, Folkerth RD, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994, 344, 82-86.
24. 24. Maeda K, Chung Y, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77, 858-863.
25. 25. Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995, 87, 1237-1245.
26. 26. Berger DP, Herbstritt L, Dengler WA, Marmé D, Mertelsmann R, Fiebig HH. Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol 1995, 6, 817-825.
27. 27. Jänicke F, Schmitt M, Pache L, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat 1993, 24, 195-208.
28. 28. Mahadevan V, Hart JR. Metastasis and angiogenesis. Acta Oncol 1990, 29, 97-103.
29. 29. Hildebrand R, Dilger I, Hörlin A, Stutte HJ. Urokinase and macrophages in tumour angiogenesis. Br J Cancer 1995, 72, 818-823.
30. 30. van Dijke CF, Brasch RC, Roberts TPL, et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 1996, 198, 813-818.
31. 31. Horak E, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet 1992, 340, 1120-1124.
32. 32. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995, 147, 9-19.
33. 33. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990, 43, 752-757.
34. 34. Holthöffer H, Virtanen I, Kariniemi AL, Hormia M, Linder E, Miettinen A. Ulex europaeus I Lectin as marker for vascular endothelium in human tissues. Lab Invest 1982, 47, 60-66.
35. 35. Schlingemann RO, Rietveld FJR, de Waal RMW, et al. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 1990, 62, 690-696.
36. 36. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34 and BNH9 antibody to H-and Y-antigens-evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 1994, 1, 82-90.
37. 37. Alles JU, Bosslet K. Immunohistochemical and immunochemical characterization of a new endothelial cell-specific antigen. J Histochem Cytochem 1986, 34, 209-214.
38. 38. Augustin HG, Kozian DH, Johnson RC. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. BioEssays 1994, 16, 901-906.
39. 39. Ruiter DJ, Schlingemann RO, Rietveld FJR, de Waal RMW. Monoclonal antibody-defined human endothelial antigens as vascular markers. J Invest Dermatol 1989, 93, 25S-32S.
40. 40. van Netten JP, Cann SA, van der Westhuizen NG. Angiogenesis and tumour growth (correspondence - reply by Folkman J). N Engl J Med 1995, 334, 920-921.
41. 41. Martin L, Holcombe C, Renshaw C, et al. Standardising the methodology of vessel density in breast cancer using immunohistochemistry and tumour microangiography. The Breast 1995, 4, 227-257 (abstract 50).
42. 42. Vermeulen PB, Verhoeven D, Fierens H, et al. Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study. Br J Cancer 1995, 71, 340-343.
43. 43. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995, 1, 1623-1634.
44. 44. Cotran RS, Gimbrone MA, Bevilacqua MP, Mendrick DL, Pober JS. Induction and detection of a human endothelial activation antigen in vivo. J Exp Med 1986, 164, 661-666.
45. 45. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 1993, 54, 363-370.
46. 46. Kumar P, Wang JM, Bernabeu C. CD105 and angiogenesis. J Pathol 1996, 178, 363-366.
47. 47. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991, 324, 1-8.
48. 48. de Jong JS, van Diest PJ, Baak JPA. Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab Invest 1995, 73, 992-926.
49. 49. Martin L, Holcombe C, Green B, Winstanley JW, Leinster SJ. Vascular heterogeneity in breast cancer assessed by microangiography and immunohistochemistry. Br J Surg 1996, 83, 702.
50. 50. Van Hoef MEHM, Knox WF, Dhesi SS, Howell A, Schor AM. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993, 29A, 1141-1145.
51. 51. Barbareschi M, Weidner N, Gasparini G, et al. Microvessel density quantification in breast carcinomas. Assessment by light microscopy vs. a computer-aided image analysis system. Appl Immunohistochem 1995, 3, 75-84.
52. 52. Vermeulen PB, Libura J, Libura M, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995, 87, 1797-1798.
53. 53. Axelsson K, Ljung BE, Moore II DH, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995, 87, 997-1008.
54. 54. Simpson JF, Ahn C, Battifora H, Esteban JM. Endothelial area as a prognostic indicator for invasive breast carcinoma. Cancer 1996, 77, 2077-2085.
55. 55. Vermeulen PB, Libura M, Libura J, et al. Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Breast Cancer Res Treat, in press.
56. 56. Berger R, Albelda SM, Berd D, Loffreda M, Whitaker D, Murphy GF. Expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) during melanoma-induced angiogenesis in vivo. J Cutan Pathol 1993, 20, 399-406.
57. 57. Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994, 86, 614-619.
58. 58. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 84, 1875-1887.
59. 59. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995, 177, 275-283.
60. 60. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GNA, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994, 74, 762-766.
61. 61. Gasparini G, Fox SB, Verderio P, et al. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 1996, 2, 1191-1198.
62. 62. Charpin C, Devictor B, Bergeret D, et al. CD31 quantitative immunocytochemical assays in breast carcinomas - correlation with current prognostic factors. Am J Clin Pathol 1995, 103, 443-448.
63. 63. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. In Rosenberg SA, ed. Impt Adv Oncol 1996, 167-190.
64. 64. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994, 69, 979-985.
65. 65. Vermeulen PB, Dirix LY, Martin M, et al. Serum levels of bFGF and VEGF in patients with metastatic solid tumors. Proc Am Soc Clin Oncol 1996, 15, 90 (abstract 26).
66. 66. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996, 2, 821-826.
67. 67. Hulka CA, Smith BL, Sgroi DC, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 1995, 197, 33-38.
68. 68. Esserman L, Weidner N, Yassa L, Hylton N. The use of breast MRI as an analytic tool to demonstrate anatomic extent, vascularity, and biological diversity in breast cancer. Proc Am Soc Clin Oncol 1996, 15, 128 (abstract 178).
69. 69. Guinebretière J-M, Le Monique G, Gavoille A, Bahi J, Contesso G. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 1994, 86, 635-636.
70. 70. Gasparini G, Bevilacqua P, Bonoldi E, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1995, 1, 1375-1383.
71. 71. Gasparini G, Barbareschi M, Boracchi P, et al. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J Sci Am 1995, 1, 131-141.
72. 72. Gasparini G, Bonoldi E, Viale G, et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 1996, 69, 205-211.
73. 73. Dirix LY, Vermeulen PB, Fierens H, et al. Long-term results of continuous treatment with recombinant interferon-α in patients with metastatic carcinoid tumors - an antiangiogenic effect? Anti-Cancer Drugs 1996, 7, 175-181.
74. 74. Munck J-N, Cvitkovic E, Piekarski J-D, et al. Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer. J Natl Cancer Inst 1991, 83, 569-575.
75. 75. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995, 13, 765-782.
76. 76. Gasparini G. Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation. Ann Oncol 1996, 7, 441-444.
77. 77. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994, 12, 454-466.
78. 78. Fox SB, Turner GDH, Gatter KC, Harris AL. The increased expression of adhesion molecules ICAM-3, E-and P-selectins on breast cancer endothelium. J Pathol 1995, 177, 369-376.